A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Conventional Concurrent Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Azeliragon (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Cantex Pharmaceuticals
Most Recent Events
- 11 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2024 As of January 2024, recruitment in dose level 1 was completed with 6 patients and 3 patients were already included in dose level 2, according to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.